Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off

PolyPid makes progress in phase 3 trial for surgical infection prevention

Published Feb 12, 2024 07:30AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters.
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio

PETACH TIKVA, Israel - PolyPid Ltd. (NASDAQ:PYPD), a biopharmaceutical company focused on improving surgical outcomes, has announced significant progress in its SHIELD II Phase 3 clinical trial, having enrolled the 100th patient. The trial is designed to evaluate the efficacy of D-PLEX100, a product candidate aimed at preventing surgical site infections (SSIs) in abdominal colorectal surgeries.

The company plans to conduct an unblinded interim analysis after approximately 400 patients complete a 30-day follow-up, which is anticipated to occur around mid-2024. Top-line results from the SHIELD II trial are expected in the latter half of 2024. Currently, about 40 centers are actively participating in the study.

D-PLEX100 utilizes PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology to deliver a sustained release of the antibiotic doxycycline directly at the surgical site. This method aims to maintain high local drug concentrations for 30 days post-operation, potentially preventing infections, including those caused by antibiotic-resistant bacteria.

The recent completion of a $16 million private placement financing, with contributions from new and existing investors, including life sciences-focused firms DAFNA Capital Management and Rosalind Advisors, has extended PolyPid's financial runway through late Q3 2024. Additionally, a potential $19 million could be secured through the exercise of warrants, contingent upon positive interim analysis results. This funding is intended to support the company through the initiation of a New Drug Application (NDA) submission for D-PLEX100.

The SHIELD II trial is being conducted across several countries, including the United States, Europe, and Israel. Its primary endpoint is the proportion of patients experiencing a surgical site infection, reintervention, or mortality within 30 days post-surgery.

The information in this article is based on a press release statement from PolyPid Ltd.

InvestingPro Insights

PolyPid Ltd. (NASDAQ:PYPD) has been actively advancing its clinical trials, but the financial health and market performance of the company are equally critical for potential investors. Here are some insights based on the latest data from InvestingPro.

InvestingPro Data:

  • Market Cap (Adjusted): As of the last twelve months, PolyPid's market capitalization stands at $33.2 million, reflecting the current valuation of the company in the market.
  • P/E Ratio (Adjusted) LTM: The price-to-earnings ratio, an indicator of the company's earnings relative to its share price, is -1.28, suggesting that the company is not currently generating profits.
  • Price / Book LTM: With a Price / Book ratio of 8.68, the company is trading at a value significantly higher than its net assets, which can be a point of concern for value-focused investors.

InvestingPro Tips:

1. PolyPid is quickly burning through cash, which is a critical factor for investors to consider, especially given the extended timeline for clinical trials and potential product commercialization.

2. The company does not pay a dividend to shareholders, which means that investors are relying solely on stock appreciation for returns.

These insights might be particularly relevant for investors considering the company's future profitability and cash flow management. PolyPid's progress in its SHIELD II Phase 3 clinical trial is a positive development, but financial metrics suggest caution. The company's valuation implies a poor free cash flow yield, and analysts do not anticipate PolyPid will be profitable this year.

Despite a strong return over the last three months, the stock price has fallen significantly over the last year, indicating potential volatility or market skepticism about the company's prospects. PolyPid operates with a moderate level of debt, which could impact its financial flexibility.

For more detailed analysis and additional InvestingPro Tips, investors can explore the full suite of insights available at There are currently 9 more tips listed on InvestingPro that could provide further depth to your investment research. Remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

PolyPid makes progress in phase 3 trial for surgical infection prevention

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your profile, will be public on and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email